IART Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 15, 2026

Report Source: 2026 1st Quarter Report

Analyst's Ratings for Integra Lifesciences Holdings Corp (IART)

Based on 17 analysts giving stock ratings to Integra Lifesciences Holdings Corp in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
12
Buy
6
Hold
40
Sell
24
Strong Sell
18
Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Corp. Stock Analysis IART

United States Health Care Small Cap Report:
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,427 full-time employees. The company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others.
Read More

Integra Lifesciences Holdings Corp (IART) Chart

Key Statistics of Integra Lifesciences Holdings Corp (IART)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$13.98$14.36

Today's Open

$14.34

Volume

864.78K

P/E Ratio (TTM)

-

52 Week Range

$8.70$16.49

Market Cap

1.03B

Avg. Volume

1.14M

Dividend Yield

-

Financial Metrics & Statements of Integra Lifesciences Holdings Corp (IART)

FAQ's for Integra Lifesciences Holdings Corp (IART)

  • According to Musaffa’s Shariah screening methodology, Integra Lifesciences Holdings Corp (IART) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.